Abnormal collagen deposition mediated by cartilage oligomeric matrix protein in the pathogenesis of oral submucous fibrosis

Abstract

Abnormal accumulation of collagen fibrils is a hallmark feature of oral submucous fibrosis (OSF). However, the precise characteristics and underlying mechanisms remain unclear, impeding the advancement of potential therapeutic approaches. Here, we observed that collagen I, the main component of the extracellular matrix, first accumulated in the lamina propria and subsequently in the submucosa of OSF specimens as the disease progressed. Using RNA-seq and Immunofluorescence in OSF specimens, we screened the cartilage oligomeric matrix protein (COMP) responsible for the abnormal collagen accumulation. Genetic COMP deficiency reduced arecoline-stimulated collagen I deposition significantly in vivo. In comparison, both COMP and collagen I were upregulated under arecoline stimulation in wild-type mice. Human oral buccal mucosal fibroblasts (hBMFs) also exhibited increased secretion of COMP and collagen I after stimulation in vitro. COMP knockdown in hBMFs downregulates arecoline-stimulated collagen I secretion. We further demonstrated that hBMFs present heterogeneous responses to arecoline stimulation, of which COMP-positive fibroblasts secrete more collagen I. Since COMP is a molecular bridge with Fibril-associated collagens with Interrupted Triple helices (FACIT) in the collagen network, we further screened and identified collagen XIV, a FACIT member, co-localizing with both COMP and collagen I. Collagen XIV expression increased under arecoline stimulation in wild-type mice, whereas it was hardly expressed in the Comp^-/- mice, even with under stimulation. In summary, we found that COMP may mediates abnormal collagen I deposition by functions with collagen XIV during the progression of OSF, suggesting its potential to be targeted in treating OSF.

References

[1] WarnakulasuriyaS, et al. . Oral potentially malignant disorders: A consensus report from an international seminar on nomenclature and classification, convened by the WHO Collaborating Centre for Oral Cancer. Oral. Dis., 2021, 27: 1862-1880.

[2] PhulariRGS, DaveEJ. A systematic review on the mechanisms of malignant transformation of oral submucous fibrosis. Eur. J. Cancer Prev., 2020, 29: 470-473.

[3] ArakeriG, et al. . Oral submucous fibrosis: An update on pathophysiology of malignant transformation. J. Oral. Pathol. Med., 2017, 46: 413-417.

[4] ShihYH, WangTH, ShiehTM, TsengYH. Oral submucous fibrosis: a review on etiopathogenesis, diagnosis, and therapy. Int J. Mol. Sci., 2019, 20: 2940.

[5] CaiX, et al. . Oral submucous fibrosis: A clinicopathological study of 674 cases in China. J. Oral. Pathol. Med., 2019, 48: 321-325.

[6] RajalalithaP, ValiS. Molecular pathogenesis of oral submucous fibrosis–a collagen metabolic disorder. J. Oral. Pathol. Med., 2005, 34: 321-328.

[7] LinY, JiangY, XianH, CaiX, WangT. Expression and correlation of the Pi3k/Akt pathway and VEGF in oral submucous fibrosis. Cell Prolif., 2023, 56: e13491.

[8] HasegawaT, OuchiT, ShibukawaY, AsodaS, NakagawaT. Etiology of oral potentially malignant disorders and squamous cell carcinoma based on cellular stress regulation and matrix stiffness. Front. Biosci., 2023, 28: 265.

[9] XuHQ, et al. . Fibrotic Matrix induces mesenchymal transformation of epithelial cells in oral submucous fibrosis. Am. J. Pathol., 2023, 193: 1208-1222.

[10] QinX, NingY, ZhouL, ZhuY. Oral submucous fibrosis: etiological mechanism, malignant transformation, therapeutic approaches and targets. Int J. Mol. Sci., 2023, 24: 4992.

[11] HuangIY, ShiehTY. [Collagen content and types in oral submucous fibrosis]. Gaoxiong Yi Xue Ke Xue Za Zhi, 1989, 5: 162-171

[12] KaurJ, et al. . Co-expression of colligin and collagen in oral submucous fibrosis: plausible role in pathogenesis. Oral. Oncol., 2001, 37: 282-287.

[13] MouwJK, OuG, WeaverVM. Extracellular matrix assembly: a multiscale deconstruction. Nat. Rev. Mol. Cell Biol., 2014, 15: 771-785.

[14] AnsorgeHL, et al. . Type XIV Collagen Regulates Fibrillogenesis: premature collagen fibril growth and tissue dysfunction in null mice. J. Biol. Chem., 2009, 284: 8427-8438.

[15] SunM, et al. . Collagen XII is a regulator of corneal stroma structure and function. Invest. Ophthalmol. Vis. Sci., 2020, 61: 61.

[16] IzuY, BirkDE. Collagen XII mediated cellular and extracellular mechanisms in development, regeneration, and disease. Front Cell Dev. Biol., 2023, 11: 1129000.

[17] KeeneDR, LunstrumGP, MorrisNP, StoddardDW, BurgesonRE. Two type XII-like collagens localize to the surface of banded collagen fibrils. J. Cell Biol., 1991, 113: 971-978.

[18] ShawLM, OlsenBR. FACIT collagens: diverse molecular bridges in extracellular matrices. Trends Biochem. Sci., 1991, 16: 191-194.

[19] IzuY, et al. . Collagen XII mediated cellular and extracellular mechanisms regulate establishment of tendon structure and function. Matrix Biol., 2021, 95: 52-67.

[20] AgarwalP, et al. . Collagen XII and XIV, new partners of cartilage oligomeric matrix protein in the skin extracellular matrix suprastructure. J. Biol. Chem., 2012, 287: 22549-22559.

[21] CuiJ, ZhangJ. Cartilage oligomeric matrix protein, diseases, and therapeutic opportunities. Int J. Mol. Sci., 2022, 23: 9253.

[22] PoseyKL, CoustryF, HechtJT. Cartilage oligomeric matrix protein: COMPopathies and beyond. Matrix Biol., 2018, 71-72: 161-173.

[23] FarinaG, et al. . Cartilage oligomeric matrix protein expression in systemic sclerosis reveals heterogeneity of dermal fibroblast responses to transforming growth factor beta. Ann. Rheum. Dis., 2009, 68: 435-441.

[24] InuiS, ShonoF, NakajimaT, HosokawaK, ItamiS. Identification and characterization of cartilage oligomeric matrix protein as a novel pathogenic factor in keloids. Am. J. Pathol., 2011, 179: 1951-1960.

[25] ThurJ, et al. . Mutations in cartilage oligomeric matrix protein causing pseudoachondroplasia and multiple epiphyseal dysplasia affect binding of calcium and collagen I, II, and IX. J. Biol. Chem., 2001, 276: 6083-6092.

[26] HoldenP, et al. . Cartilage oligomeric matrix protein interacts with type IX collagen, and disruptions to these interactions identify a pathogenetic mechanism in a bone dysplasia family. J. Biol. Chem., 2001, 276: 6046-6055.

[27] RayJG, ChatterjeeR, ChaudhuriK. Oral submucous fibrosis: A global challenge. Rising incidence, risk factors, management, and research priorities. Periodontol 2000, 2019, 80: 200-212.

[28] KondaiahP, PantI, KhanI. Molecular pathways regulated by areca nut in the etiopathogenesis of oral submucous fibrosis. Periodontol 2000, 2019, 80: 213-224.

[29] LiJ, et al. . YAP-induced endothelial-mesenchymal transition in oral submucous fibrosis. J. Dent. Res., 2019, 98: 920-929.

[30] GuoZX, et al. . A biomaterial-based therapy using a sodium hyaluronate/bioglass composite hydrogel for the treatment of oral submucous fibrosis. Acta Biomater., 2023, 157: 639-654.

[31] YangX, et al. . Stromal thrombospondin 1 suppresses angiogenesis in oral submucous fibrosis. Int J. Oral. Sci., 2024, 16: 17.

[32] MehtaCH, et al. . Polyphenol-based targeted therapy for oral submucous fibrosis. Inflammopharmacology, 2023, 31: 2349-2368.

[33] YuCH, et al. . XIST/let-7i/HMGA1 axis maintains myofibroblasts activities in oral submucous fibrosis. Int J. Biol. Macromol., 2023, 232: 123400.

[34] LiaoYW, YuCC, HsiehCW, ChaoSC, HsiehPL. Aberrantly downregulated FENDRR by arecoline elevates ROS and myofibroblast activation via mitigating the miR-214/MFN2 axis. Int J. Biol. Macromol., 2024, 264: 130504.

[35] LeeYH, et al. . α-Mangostin inhibits the activation of myofibroblasts via downregulation of Linc-ROR-mediated TGFB1/Smad signaling. Nutrients, 2023, 15: 1321.

[36] PerlishJS, LemlichG, FleischmajerR. Identification of collagen fibrils in scleroderma skin. J. Invest. Dermatol., 1988, 90: 48-54.

[37] BinnieWH, CawsonRA. A new ultrastructural finding in oral submucous fibrosis. Br. J. Dermatol., 1972, 86: 286-290.

[38] TomA, et al. . Ultrastructural changes of collagen in different histopathological grades of oral submucous fibrosis. J. Pharm. Bioallied Sci., 2019, 11: S309-S313.

[39] AgarwalP, et al. . Enhanced deposition of cartilage oligomeric matrix protein is a common feature in fibrotic skin pathologies. Matrix Biol., 2013, 32: 325-331.

[40] FarinaG, LemaireR, KornJH, WidomRL. Cartilage oligomeric matrix protein is overexpressed by scleroderma dermal fibroblasts. Matrix Biol., 2006, 25: 213-222.

[41] MoonSJ, BaeJM, ParkKS, TagkopoulosI, KimKJ. Compendium of skin molecular signatures identifies key pathological features associated with fibrosis in systemic sclerosis. Ann. Rheum. Dis., 2019, 78: 817-825.

[42] GatselisNK, et al. . Serum cartilage oligomeric matrix protein and Golgi Protein-73: New diagnostic and predictive tools for liver fibrosis and hepatocellular cancer?. Cancers, 2021, 13: 3510.

[43] CharreC, LevreroM, ZoulimF, ScholtèsC. Non-invasive biomarkers for chronic hepatitis B virus infection management. Antivir. Res., 2019, 169: 104553.

[44] VugaLJ, et al. . Cartilage oligomeric matrix protein in idiopathic pulmonary fibrosis. PLoS One, 2013, 8: e83120.

[45] SchulzJN, et al. . COMP-assisted collagen secretion–a novel intracellular function required for fibrosis. J. Cell Sci., 2016, 129: 706-716

[46] MagdalenoF, et al. . Cartilage oligomeric matrix protein participates in the pathogenesis of liver fibrosis. J. Hepatol., 2016, 65: 963-971.

[47] ShouldersMD, RainesRT. Collagen structure and stability. Annu. Rev. Biochem, 2009, 78: 929-958.

[48] Ricard-BlumS. The collagen family. Cold Spring Harb. Perspect. Biol., 2011, 3: a004978.

[49] WälchliC, KochM, ChiquetM, OdermattBF, TruebB. Tissue-specific expression of the fibril-associated collagens XII and XIV. J. Cell Sci., 1994, 107: 669-681.

[50] SandbergMM. Matrix in cartilage and bone development: current views on the function and regulation of major organic components. Ann. Med., 1991, 23: 207-217.

[51] VaughanL, et al. . D-periodic distribution of collagen type IX along cartilage fibrils. J. Cell Biol., 1988, 106: 991-997.

[52] van der RestM, MayneR. Type IX collagen proteoglycan from cartilage is covalently cross-linked to type II collagen. J. Biol. Chem., 1988, 263: 1615-1618.

[53] HalászK, KassnerA, MörgelinM, HeinegårdD. COMP acts as a catalyst in collagen fibrillogenesis. J. Biol. Chem., 2007, 282: 31166-31173.

[54] ParkS, RanjbarvaziriS, ZhaoP, ArdehaliR. Cardiac fibrosis is associated with decreased circulating levels of full-length CILP in heart failure. JACC Basic Transl. Sci., 2020, 5: 432-443.

[55] WangY, et al. . COMP promotes pancreatic fibrosis by activating pancreatic stellate cells through CD36-ERK/AKT signaling pathways. Cell Signal, 2024, 118: 111135.

[56] CaiX, LiM, ZhongY, YangW, LiangZ. COMP improves ang-II-induced atrial fibrillation via TGF-β SIGNALING PATHway. Cardiovasc. Toxicol., 2023, 23: 305-316.

[57] LiQ, et al. . HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways. J. Exp. Clin. Cancer Res., 2018, 37: 231.

[58] ShenW, et al. . Sangerbox: A comprehensive, interaction-friendly clinical bioinformatics analysis platform. iMeta, 2022, 1: e36.

Funding

National Natural Science Foundation of China (National Science Foundation of China)(81974150)

RIGHTS & PERMISSIONS

The Author(s)